Source: everything possible / Shutterstock.com
Tevogen Bio (NASDAQ:TVGN) stock experiences a surge today following the introduction of a new Head of Investor Relations and Corporate Development.
Tapan V Shah takes the reins as the new Head of Investor Relations and Corporate Development at Tevogen Bio, bringing along 25 years of experience in various roles with Wall Street firms.
Shah’s professional journey includes roles such as the Director of Relationship Management at Citigroup’s (NYSE:C) Client organization and positions at Morgan Stanley’s (NYSE:MS) asset management business and Goldman Sachs’ (NYSE:GS) Investment Banking Division.
Ryan Saadi, Tevogen Bio’s founder and CEO, expressed optimism about Shah’s appointment, highlighting his financial expertise and ability to build crucial relationships in the industry.
“Mr. Shah’s extensive background in financial services, paired with his ability to forge trusted-advisor relationships, will steer our company through its upcoming stages of growth and play a crucial role as we venture into new areas of the healthcare ecosystem.”
Impact on TVGN Stock Performance
Investor enthusiasm over Shah’s arrival at Tevogen Bio has triggered a flurry of trading activity in TVGN stock today. Trading volume has soared to over 15 million shares, significantly surpassing the daily average of 24,000 shares. Additionally, TVGN’s float stands at approximately 4.09 million units.
As of Thursday morning, TVGN stock has surged by a notable 46.3%.
For those interested in the latest stock market updates, various stories, including movements in cannabis stocks like View (NASDAQ:VIEW) stock, are available below.
Additional Stock Market News for Thursday
On Penny Stocks and Low-Volume Stocks: InvestorPlace refrains from discussing companies with a market cap below $100 million or trading less than 100,000 shares daily, due to their susceptibility to potential scams and market manipulation.
Learn More: Penny Stocks — Strategies to Avoid Scams
As of the publication date, William White did not hold any positions (directly or indirectly) in the securities discussed in this article. The views expressed are solely those of the author and adhere to the InvestorPlace.com Editorial Guidelines.